Released Mar 6, 2018, before the open
10-K filed Mar 6, 2018, 65 days after period end · 0001144204-18-013053
Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$4.31M$4.31M derived+106.9% vs Q4 2016−42.8% vs Q3 2017
Net Income-$13.31M-$13.31M derivedN/M vs Q4 2016N/M vs Q3 2017
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$915,000+609.3%
Operating Incomederived-$9,582,000N/M
Operating Cash Flowderived$17,590,000N/M
Free Cash Flowderived$17,300,000N/M
Margins · derived
Gross margin21.3%+15.1 pt vs Q4 2016
Operating margin-222.6%+196.5 pt vs Q4 2016
Net margin-309.1%−183.0 pt vs Q4 2016
What the release said
The release
Same quarter
| Metric | Q4 2017dderived from reported figures | Q4 2016dderived from reported figures | Q4 2015dderived from reported figures | Q4 2014dderived from reported figures |
|---|---|---|---|---|
| Revenue | $4.31M | $2.08M | $0.00 | — |
| Net Income | -$13.31M | -$2.62M | $72.90M | -$8.47M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR